From Nasdaq: 2024-03-26 11:24:04

Moderna’s next-generation COVID-19 vaccine, mRNA-1283, has successfully met the primary endpoints in the NextCOVE Phase 3 clinical trial. The study, involving 11,400 participants aged 12 and older, showed a positive immune response to SARS-CoV-2 compared to the licensed vaccine mRNA-1273.222. Common side effects reported include injection site pain, headache, fatigue, myalgia, and chills. Moderna plans to release a detailed analysis of the trial data for mRNA-1283 at its Vaccines Day event on March 27 and in future scientific conferences.



Read more at Nasdaq: Moderna’s MRNA-1283 COVID-19 Vaccine Design Meets Primary Endpoints In Phase 3 Clinical Trial